百洋醫藥(301015.SZ)簽署商業化合作戰略協議
格隆匯11月19日丨百洋醫藥(301015.SZ)發佈公吿,為建立長期友好戰略合作關係,發揮雙方的資源優勢,近日,百洋醫藥與廣東瑞迪奧科技有限公司簽署了《商業化合作戰略協議》;百洋醫藥控股子公司北京百洋國勝醫療器械有限公司與北京邁迪斯醫療技術有限公司簽署了《商業化合作戰略協議》。
百洋醫藥致力於以科技創新優化醫療場景,解決未被滿足的臨牀需求,本次戰略合作是合作伙伴對公司商業化能力的高度認可,有助於提高公司的品牌影響力和市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.